CD274 and hepatocellular carcinoma: CheckMate-459, KEYNOTE-224, and IMbrave150 studies showed higher response rates for PD-L1 positive advanced HCC patients treated with immunotherapy, while the CheckMate-040 study showed no significant difference between PD-L1 positive and negative patients treated with nivolumab (11, 14).